A reduction of HbAs1c after 3 months predicts 2-year responsiveness to sitagliptin treatment

Takeshi Nishimura, Shu Meguro, Risa Sekioka, Karin Tanaka, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Toshihide Kawai, Hiroshi Itoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of

Original languageEnglish
Pages (from-to)2981-2989
Number of pages9
JournalInternal Medicine
Volume54
Issue number23
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Type 2 Diabetes Mellitus
Outpatients
Retrospective Studies
Glucose
Therapeutics
Sitagliptin Phosphate

Keywords

  • Diabetes
  • Dipeptidyl peptidase-4 inhibitor
  • Glycemic control
  • HbA1c
  • Hemoglobin
  • Sitagliptin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A reduction of HbAs1c after 3 months predicts 2-year responsiveness to sitagliptin treatment. / Nishimura, Takeshi; Meguro, Shu; Sekioka, Risa; Tanaka, Karin; Saisho, Yoshifumi; Irie, Junichiro; Tanaka, Masami; Kawai, Toshihide; Itoh, Hiroshi.

In: Internal Medicine, Vol. 54, No. 23, 01.12.2015, p. 2981-2989.

Research output: Contribution to journalArticle

@article{60062cee265f4a839820e83ca741c682,
title = "A reduction of HbAs1c after 3 months predicts 2-year responsiveness to sitagliptin treatment",
abstract = "Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-na{\"i}ve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of",
keywords = "Diabetes, Dipeptidyl peptidase-4 inhibitor, Glycemic control, HbA1c, Hemoglobin, Sitagliptin",
author = "Takeshi Nishimura and Shu Meguro and Risa Sekioka and Karin Tanaka and Yoshifumi Saisho and Junichiro Irie and Masami Tanaka and Toshihide Kawai and Hiroshi Itoh",
year = "2015",
month = "12",
day = "1",
doi = "10.2169/internalmedicine.54.4144",
language = "English",
volume = "54",
pages = "2981--2989",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "23",

}

TY - JOUR

T1 - A reduction of HbAs1c after 3 months predicts 2-year responsiveness to sitagliptin treatment

AU - Nishimura, Takeshi

AU - Meguro, Shu

AU - Sekioka, Risa

AU - Tanaka, Karin

AU - Saisho, Yoshifumi

AU - Irie, Junichiro

AU - Tanaka, Masami

AU - Kawai, Toshihide

AU - Itoh, Hiroshi

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of

AB - Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of

KW - Diabetes

KW - Dipeptidyl peptidase-4 inhibitor

KW - Glycemic control

KW - HbA1c

KW - Hemoglobin

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84948960117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948960117&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.54.4144

DO - 10.2169/internalmedicine.54.4144

M3 - Article

VL - 54

SP - 2981

EP - 2989

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 23

ER -